We present an unusual case of complement-mediated thrombotic microangiopathy (formerly known as atypical hemolytic uremic syndrome) associated with inflammatory disease in a young patient. A 26-year-old male patient with no significant past medical history presented to our emergency department with a four-week history of diffuse, moderate, cramping, non-radiating abdominal pain with no known aggravating or relieving factors. Abdominal pain was associated with nausea, vomiting, and bloody stools. His physical examination revealed pale conjunctiva, tachycardia, and mild tenderness in the lower abdomen. The patient's laboratory results indicated severe anemia with a hemoglobin level of 2.9 g/dL, an elevated white blood cell count of 52.86 K/uL, a low platelet count of 107 K/uL, and evidence of acute kidney injury, with a blood urea nitrogen level of 87.0 mg/dL and a serum creatinine level of 8.32 mg/dL. Further work-up showed hemolysis, characterized by low haptoglobin levels, elevated lactate dehydrogenase, and a positive direct Coombs test for both anti-IgG and anti-C3 antibodies. A computed tomography angiogram (CTA) of the abdomen and pelvis showed pancolitis. Severe inflammation was noted during a flexible sigmoidoscopy, and pathology results revealed chronic inflammation/chronic colitis. A renal biopsy performed showed thrombotic microangiopathic changes with complement deposition. The patient was started on eculizumab, which ultimately resulted in improvements in anemia, thrombocytopenia, and renal function. Our case stands out as the complexity of the diagnosis warrants awareness of complement-mediated thrombotic microangiopathy (TMA). The introduction of eculizumab, a terminal complement blockade therapy, has revolutionized the management of complement-mediated TMA, as early initiation of eculizumab treatment has shown significant reductions in disease progression to end-stage kidney disease and its related complications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882344 | PMC |
http://dx.doi.org/10.7759/cureus.78447 | DOI Listing |
Cureus
February 2025
Nephrology, State University of New York Downstate Health Sciences University, Brooklyn, USA.
We present an unusual case of complement-mediated thrombotic microangiopathy (formerly known as atypical hemolytic uremic syndrome) associated with inflammatory disease in a young patient. A 26-year-old male patient with no significant past medical history presented to our emergency department with a four-week history of diffuse, moderate, cramping, non-radiating abdominal pain with no known aggravating or relieving factors. Abdominal pain was associated with nausea, vomiting, and bloody stools.
View Article and Find Full Text PDFBioDrugs
February 2025
King's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, and King's College London, London, UK.
Eculizumab, a humanized monoclonal antibody targeting complement C5, is the first approved drug for complement-mediated diseases and indicated to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorder. The introduction of eculizumab has improved the prognosis of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome to near-normal life expectancy and quality of life. Administration of eculizumab resulted in a rapid and sustained reduction in hemolytic activity and a consequent risk of thrombosis in paroxysmal nocturnal hemoglobinuria, and thrombotic microangiopathy in atypical hemolytic uremic syndrome, respectively.
View Article and Find Full Text PDFEmerg Microbes Infect
December 2025
Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Complement hyperactivation and thrombotic microangiopathy are closely associated with severe COVID-19. Endothelial dysfunction is a key mechanism underlying thrombotic microangiopathy. To address the relationship between endothelial injury, complement activation and thrombotic microangiopathy of severe COVID-19, we wonder whether, and if so, what and how SARS-CoV-2 factors make endothelial cells (ECs) sensitive to complement-mediated cytotoxicity.
View Article and Find Full Text PDFJ Immunol Methods
February 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:
Complement functional assays are essential first-tier tests for a gamut of disorders spanning from inborn errors of the immune system which lead to recurrent severe infections, to angioedema attacks, presentation of autoimmune disease, thrombotic microangiopathies and rare kidney disorders. These assays evaluate the activity of the three complement pathways and specific complement components, which helps in differential diagnosis and monitoring disease progression. The rising use of complement inhibitors for treating complement-mediated thrombotic microangiopathies has heightened the demand for personalized treatment plans and laboratory assessment of complement blockage.
View Article and Find Full Text PDFJ Am Soc Nephrol
January 2025
Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Thrombotic microangiopathy (TMA) is a challenging and serious complication of kidney transplantation that significantly impacts graft and patient survival, occurring in 0.8-15% of transplant recipients. TMA is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury due to endothelial damage and microthrombi formation in small vessels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!